Skip to Content

Loncastuximab tesirine FDA Approval Status

FDA Approved: No
Generic name: loncastuximab tesirine
Company: ADC Therapeutics SA
Treatment for: Diffuse Large B-cell Lymphoma

Loncastuximab tesirine (Lonca, formerly ADCT-402) is an antibody drug conjugate (composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin) in development for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Development Timeline for loncastuximab tesirine

DateArticle
Sep 24, 2020ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.